Firm Receives First Main Buy Order in Saudi Arabia
TORRANCE, Calif., Nov. 17, 2022 /PRNewswire/ — Emmaus Life Sciences, Inc.(OTCQB: EMMA), a frontrunner in sickle cell illness therapy, introduced right now that it has been issued a Registration Certificates from the Registration Committee for Pharmaceutical Firms & their Merchandise of the Qatar Ministry of Public Well being granting advertising and marketing authorization for the industrial distribution and sale of Endari® within the nation. The corporate additionally introduced that it acquired its first main buy order from its distributor within the Kingdom of Saudi Arabia, the place Endari® is on the market on an early entry foundation solely.
Endari® is accepted within the U.S., the United Arab Emirates, Israel, and the State of Qatar to scale back the acute problems of sickle cell illness in grownup and pediatric sufferers 5 years of age and older. Endari® is on the market on an early entry foundation in Bahrain, Kuwait and the Kingdom of Saudi Arabia pending official discover of motion on Emmaus’s advertising and marketing authorization functions in these nations.
Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Government Officer of Emmaus, commented “We’re grateful that Qatari officers made entry to Endari simpler for the sickle cell sufferers within the nation. We’ll proceed to try in our mission to afford elevated availability of Endari within the Center East and North Africa area with its massive and underserved sickle cell illness affected person inhabitants.”
George Sekulich, Senior Vice President of International Commercialization of Emmaus, added “The approval from the Ministry of Public Well being is one other validation of the protection and efficacy of Endari. We sit up for working with our distribution associate to make Endari out there to the sickle cell illness sufferers within the emirate.”
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical firm engaged within the discovery, growth, advertising and marketing and sale of revolutionary remedies and therapies, together with these within the uncommon and orphan illness classes. For extra info, please go to www.emmausmedical.com.
About Endari® (prescription grade L-glutamine oral powder)
Indication – Endari® is indicated to scale back the acute problems of sickle cell illness in grownup and pediatric sufferers 5 years of age and older.
Essential Security Info
The most typical adversarial reactions (incidence >10 %) in medical research have been constipation, nausea, headache, belly ache, cough, ache in extremities, again ache, and chest ache.
Hostile reactions resulting in therapy discontinuation included one case every of hypersplenism, belly ache, dyspepsia, burning sensation, and sizzling flash.
The security and efficacy of Endari® in pediatric sufferers with sickle cell illness youthful than 5 years of age has not been established.
For extra info, please see full Prescribing Info of Endari® at: www.ENDARIrx.com/PI.
About Sickle Cell Illness
There are roughly 100,000 folks dwelling with sickle cell illness (SCD) in america and tens of millions extra globally. The sickle gene is present in each ethnic group, not simply amongst these of African descent; and in america an estimated 1-in-365 African People and 1-in-16,300 Hispanic People are born with SCD.1 The genetic mutation answerable for SCD causes a person’s purple blood cells to distort right into a “C” or a sickle form, lowering their potential to move oxygen all through the physique. These sickled purple blood cells break down quickly, turn out to be very sticky, and develop a propensity to clump collectively, which causes them to turn out to be caught and trigger harm inside blood vessels. The result’s lowered blood move to distal organs, which ends up in bodily signs of incapacitating ache, tissue and organ harm, and early loss of life.2
1Supply: Information & Statistics on Sickle Cell Illness – Nationwide Heart on Start Defects and Developmental Disabilities, Facilities for Illness Management and Prevention, December 2020.
2Supply: Committee on Addressing Sickle Cell Illness – A Strategic Plan and Blueprint for Motion — Nationwide Academy of Sciences Press, 2020.
This press launch accommodates forward-looking statements made pursuant to the protected harbor provisions of the Non-public Securities Litigation Reform Act of 1995, as amended, together with statements concerning the Product Registration acquired from the Qatar Ministry of Public Well being. These forward-looking statements are topic to quite a few assumptions, dangers and uncertainties which change over time, together with the danger that the Product Registration doesn’t end in vital gross sales of Endari® in Qatar and uncertainties associated to Emmaus’ working capital and talent to hold on its present operations and procure wanted financing and different components beforehand disclosed within the firm’s stories filed with the Securities and Change Fee, and precise outcomes could differ materially. Such forward-looking statements converse solely as of the date they’re made, and Emmaus assumes no obligation to replace them, besides as could also be required by regulation.
Emmaus Life Sciences, Inc.
Chief Working Officer
(310) 214-0065, Ext. 1130
SOURCE Emmaus Life Sciences, Inc.
Firm Codes: OTC-QX:EMMA, OTC-BB:EMMA, OTC-PINK:EMMA, OTC-QB:EMMA